PC
RPRX

PointState Capital’s Repros Therapeutics Inc. RPRX Stock Holding History

PointState Capital’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-270,000
Closed -$4.94M – 194
2013
Q4 		$4.94M Buy
+270,000
New +$5.1M 0.06% 114

Other funds holding RPRX

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

PointState Capital's RPRX Position: Q1 2014 in Review

PointState Capital sold out of Repros Therapeutics Inc. (RPRX) in Q1 2014, closing a stake of 270,000 shares — an estimated $4.94M sold.

PointState Capital first reported a position in RPRX in Q4 2013 and held it in 1 quarter. The position peaked at $4.94M in Q4 2013. 80 funds tracked by Wall St. Rank hold RPRX as of Q1 2014.

  • PointState Capital reported no remaining Repros Therapeutics Inc. position as of Q1 2014 after selling out during the quarter.
  • PointState Capital sold 270,000 Repros Therapeutics Inc. shares in Q1 2014, an estimated $4.94M.
  • PointState Capital first reported a position in Repros Therapeutics Inc. in Q4 2013 and held it in 1 quarter.
  • PointState Capital's Repros Therapeutics Inc. position peaked at $4.94M in Q4 2013.
  • 80 funds tracked by Wall St. Rank held Repros Therapeutics Inc. as of Q1 2014.

Based on PointState Capital's 13F filing for Q1 2014, filed 15 May 2014.